Table 1.
Subject inclusions
| Timepoints | Action | RABV-Exposed Group n (%) | RABV-Unexposed Group n (%) | Total n (%) |
|---|---|---|---|---|
| D0 | Blood sampling and vaccination | 86 (100.0) | 89 (100.0) | 175 (100.0) |
| eRIG administration | 86 (100.0) | 3 (3.4) (*) | 89 (50.9) | |
| D3 | Vaccination | 86 (100.0) | 89 (100.0) | 175 (100.0) |
| D7 | Blood sampling | 84 (97.7) | 88 (98.9) | 172 (98.3) |
| Vaccination | 86 (100.0) | 89 (100.0) | 175 (100.0) | |
| D14 | Blood sampling | 84 (97.7) | 85 (95.5) | 169 (96.6) |
| M6 | Blood sampling | 79 (91.9) | 78 (87.6) | 157 (89.7) |
| M12 | Blood sampling (**) | 78 (90.7) | 71 (79.8) | 149 (85.1) |
| Individuals included in analysis (#) | 78 (90.7) | 70 (78.6) | 148 (84.6) |
(*) These three individuals in rabies virus (RABV)-unexposed group who received eRIG were not included in the analysis comparing the neutralizing antibody (nAb) and T cell responses between RABV-exposed versus RABV-unexposed group. (**) Individuals present throughout the entire study timepoints. In total, 26 participants withdrew from the study for various causes not related to vaccination, including personal matters, discomfort during blood collection, and COVID-19 lockdown. None was excluded due to PEP side effects. (#) One subject in RABV-unexposed group had a RABV nAb > 0.5 IU/mL at D0, before receiving PEP, so we excluded this patient from all data analysis. eRIG equine rabies immunoglobulin.